Form 4: Sight Sciences' Chief Technology Officer Receives Stock Grant

David Badawi, Chief Technology Officer of Sight Sciences, Inc., reports the acquisition of 98,566 shares of common stock through a restricted stock unit (RSU) grant.

Summary

• David Badawi, the Chief Technology Officer of Sight Sciences, Inc., filed a Form 4 to report changes in beneficial ownership.
• On March 11, 2025, Badawi acquired 98,566 shares of common stock through a grant of restricted stock units (RSUs).
• These RSUs vest in 16 equal quarterly installments starting March 31, 2025, and continuing until December 31, 2028, contingent upon Badawi's continued service to the company.
• Each RSU represents the right to receive one share of Sight Sciences' common stock.
• The number of RSUs granted was determined by dividing $275,000 by the closing price of the common stock on the grant date.
• Following the reported transaction, Badawi beneficially owns 1,842,684 shares of Sight Sciences' common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The vesting schedule suggests a long-term commitment from the CTO, which is generally viewed positively.

Positives

• The RSU grant aligns the CTO's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from the CTO.
• The grant is part of a pre-existing incentive plan, suggesting a structured approach to executive compensation.

Future Outlook

The vesting of the RSUs is contingent upon the Reporting Person's continued service to the Issuer through each vesting date.

Industry Context

Stock grants are a common practice in the technology and biotech industries to incentivize and retain key executives. The size and vesting schedule of the grant are typical for a CTO role in a company of Sight Sciences' size and stage.

Comparison to Industry Standards

• Stock grants for CTOs in similar-sized companies in the medical device industry typically range from $200,000 to $500,000 annually, vesting over a 3-5 year period.
• Companies like InMode Ltd. and STAAR Surgical Company also utilize RSU grants as part of their executive compensation packages.
• The vesting schedule of 16 equal quarterly installments over four years is a standard practice to ensure long-term commitment.

Stakeholder Impact

• The RSU grant could positively impact shareholder confidence by aligning executive interests with company performance.
• Employees may view the grant as a positive sign of the company's commitment to its leadership team.
• The grant has no immediate impact on customers, suppliers, or creditors.

Key Dates